In 2022, domestic and foreign pharmaceutical companies are setting off a "wave of layoffs"

In recent years, with the increasing competition in the pharmaceutical market, domestic and foreign pharmaceutical companies have begun to use strategic restructuring to improve efficiency and reduce costs, such as cutting pipelines, reducing teams, and restructuring
.
In this context, the voices about salary cuts and layoffs by pharmaceutical companies have also begun to be heard
.
According to statistics from Fierce Biotech, as of April 6, more than 30 pharmaceutical companies have announced plans to downsize their teams this year
.
It involves Novartis, Sanofi, Merck, Gilead, Biogen and Daiichi Sankyo and many other companies
.
Among them, in early April, Novartis announced that it would integrate the pharmaceutical and oncology business units and create two independent business organizations with stronger geographic focus - the US innovative drug department and the international innovative drug department
.
At the same time, it plans to lay off thousands of jobs worldwide
.
Currently, Novartis has about 108,000 employees worldwide
.
At the end of March, AstraZeneca issued an email about layoffs, because the newly established respiratory, digestive and autoimmune divisions were merged last month.
Therefore, the personnel adjustment brought about by organizational streamlining is also a routine action
.
Compensation plan N+3, you can directly take the money and leave, or wait for a job transfer
.
That same month, Biogen confirmed it may lay off about 10% of its workforce, STAT News reported
.
A spokesman for Biogen said that the company did not publicly provide details about the layoffs, only that “Biogen is implementing cost-cutting measures, and through layoffs, it is expected to save $500 million a year
.
” But there are reports that as of early March, Biogen had laid off more than 100 employees
.
In addition, Gilead filed a layoff notice with Worker Adjustment and Retraining Notification in New Jersey, which will lay off 114 employees in Morris Plains, New Jersey
.
In China, under the influence of the policy, news of layoffs, dismissal of teams, and salary suspensions in pharmaceutical companies have been coming this year.

.
According to incomplete statistics, as of April 19, the 2021 annual reports disclosed by nearly 200 listed pharmaceutical companies in China show that the total number of employees in about 50 companies has declined to varying degrees
.
Companies that have significantly reduced staff include both pharmaceutical distribution companies such as Shanghai Pharmaceuticals, and biopharmaceutical companies such as Sunshine Guojian
.
Judging from the motivation of major pharmaceutical companies to lay off staff, the main reason is not only affected by the epidemic, but also related to the pressure faced by the company
.
At present, the competition in the pharmaceutical market is fierce, and the medical reform policy continues to advance, which is forcing enterprises to speed up transformation and upgrading.
At this time, it is also expected that enterprises will cut costs, optimize the structure, and focus on advantageous businesses
.
With changes in policies and markets, the development strategies of pharmaceutical companies cannot remain unchanged.
Therefore, for pharmaceutical companies, it is necessary to continuously improve their innovation capabilities and continuously enrich their product pipelines in order to have stronger competitiveness in the fierce market competition
.
For medical professionals, only by continuously improving their professional ability and keeping up with the development of pharmaceutical companies can they play their value in the development process of the company
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.